Elafibranor–ACC Inhibitor Combination for Multi-Pathway Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory, metabolic, fibrotic, and cholestatic diseases are inadequate in addressing multiple pathways simultaneously, leading to suboptimal therapeutic outcomes.
Innovation Solution
A combination therapy comprising Elafibranor, a PPAR agonist, and an Acetyl-CoA carboxylase (ACC) inhibitor such as CP-640186, Gemcabene, or GS-0976, targeting parallel or complementary key pathways involved in these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monotherapy with a single agent is used, then the treatment approach is simple, but the therapeutic outcome is suboptimal because multiple pathways are not addressed simultaneously
Solution Approach 1:
The patent combines elafibranor (a PPARα/δ agonist) with an ACC inhibitor in a single combination product to simultaneously target multiple pathological pathways involved in inflammatory, metabolic, fibrotic and cholestatic diseases. This merging of two therapeutic agents addresses the limitation of monotherapy by engaging multiple disease-relevant pathways concurrently, thereby improving therapeutic outcomes while managing complexity through a fixed-ratio combination formulation.
2Reliability
If multiple pathways are targeted simultaneously, then the therapeutic outcome is improved, but the treatment complexity increases
Solution Approach 1:
The combination product serves multiple therapeutic functions simultaneously: elafibranor activates PPARα and PPARδ to regulate lipid metabolism and reduce inflammation, while the ACC inhibitor suppresses fatty acid synthesis. This multi-functional approach allows a single treatment regimen to address diverse pathological mechanisms (inflammation, metabolism, fibrosis, cholestasis) that would otherwise require multiple separate therapies, thereby improving reliability without proportionally increasing treatment complexity.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to a combination product and its use in therapy.